Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty.
Colwell CW Jr, Berkowitz SD, Lieberman JR, Comp PC, Ginsberg JS, Paiement G, McElhattan J, Roth AW, Francis CW; EXULT B Study Group. Colwell CW Jr, et al. Among authors: ginsberg js. J Bone Joint Surg Am. 2005 Oct;87(10):2169-77. doi: 10.2106/JBJS.D.02184. J Bone Joint Surg Am. 2005. PMID: 16203879 Clinical Trial.
Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.
Colwell CW Jr, Berkowitz SD, Davidson BL, Lotke PA, Ginsberg JS, Lieberman JR, Neubauer J, McElhattan JL, Peters GR, Francis CW. Colwell CW Jr, et al. Among authors: ginsberg js. J Thromb Haemost. 2003 Oct;1(10):2119-30. doi: 10.1046/j.1538-7836.2003.00368.x. J Thromb Haemost. 2003. PMID: 14521593 Free article. Clinical Trial.
Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.
Heit JA, Colwell CW, Francis CW, Ginsberg JS, Berkowitz SD, Whipple J, Peters G; AstraZeneca Arthroplasty Study Group. Heit JA, et al. Among authors: ginsberg js. Arch Intern Med. 2001 Oct 8;161(18):2215-21. doi: 10.1001/archinte.161.18.2215. Arch Intern Med. 2001. PMID: 11575978 Clinical Trial.
Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.
Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P, Jackson S, Turpie AG, MacKinnon B, Hirsh J, Gent M; Fixed-Dose Heparin (FIDO) Investigators. Kearon C, et al. Among authors: ginsberg js. JAMA. 2006 Aug 23;296(8):935-42. doi: 10.1001/jama.296.8.935. JAMA. 2006. PMID: 16926353 Clinical Trial.
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.
RE-MOBILIZE Writing Committee; Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA. RE-MOBILIZE Writing Committee, et al. Among authors: ginsberg js. J Arthroplasty. 2009 Jan;24(1):1-9. doi: 10.1016/j.arth.2008.01.132. Epub 2008 Apr 14. J Arthroplasty. 2009. PMID: 18534438 Clinical Trial.
294 results